{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:26:03Z","timestamp":1790774763897,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Sultan Qaboos UniversitySultan Qaboos University (SQU)","award":["SR\/SCI\/CHEM\/15\/01"],"award-info":[{"award-number":["SR\/SCI\/CHEM\/15\/01"]}]},{"name":"Arab-German Young Academy of Sciences and Humanities","award":["TP_2017_27"],"award-info":[{"award-number":["TP_2017_27"]}]},{"name":"Arab-German Young Academy of Sciences and Humanities","award":["TP_2018_08"],"award-info":[{"award-number":["TP_2018_08"]}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.drudis.2018.09.021","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T13:32:51Z","timestamp":1538573571000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-8419","authenticated-orcid":false,"given":"Younis","family":"Baqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-6624","authenticated-orcid":false,"given":"Christa E.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2018.09.021_bib0005","first-page":"1","article-title":"Deaths: final data for 2015","volume":"66","author":"Murphy","year":"2017","journal-title":"Natl. Vital Stat. Rep."},{"key":"10.1016\/j.drudis.2018.09.021_bib0010","series-title":"The Top 10 Causes of Death","author":"WHO","year":"2018"},{"key":"10.1016\/j.drudis.2018.09.021_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Naghavi","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2018.09.021_bib0020","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/pr.117.014530","article-title":"Platelet signaling and disease: targeted therapy for thrombosis and other related diseases","volume":"70","author":"Yeung","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2018.09.021_bib0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: emphasis on preserving haemostasis","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0035","first-page":"CD005158","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events","volume":"12","author":"Squizzato","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drudis.2018.09.021_bib0040","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"Saito","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.drudis.2018.09.021_bib0045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.crci.2012.05.006","article-title":"The story of clopidogrel and its predecessor, ticlopidine: could these major antiplatelet and antithrombotic drugs be discovered and developed today?","volume":"15","author":"Maffrand","year":"2012","journal-title":"C. R. Chim."},{"key":"10.1016\/j.drudis.2018.09.021_bib0050","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1177\/106002809302700915","article-title":"Ticlopidine and antiplatelet therapy","volume":"27","author":"Flores-Runk","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.drudis.2018.09.021_bib0055","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2018.09.021_bib0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fphar.2018.00066","article-title":"P2Y12 receptors in tumorigenesis and metastasis","volume":"9","author":"Ballerini","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17425255.2018.1428557","article-title":"P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosis","volume":"14","author":"Kupka","year":"2018","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1248\/yakushi.16-00262","article-title":"Neuropharmacological study of ATP receptors, especially in the relationship between glia and pain","volume":"137","author":"Inoue","year":"2017","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.drudis.2018.09.021_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bcp.2017.07.016","article-title":"The therapeutic potential of purinergic signalling","volume":"151","author":"Burnstock","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fphar.2017.00661","article-title":"Purinergic signalling: therapeutic developments","volume":"8","author":"Burnstock","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0085","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.pcad.2018.01.001","article-title":"The timing of P2Y12 inhibitor initiation in the treatment of ACS? Does the evidence exist in this era?","volume":"60","author":"Golwala","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.drudis.2018.09.021_bib0090","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14656566.2018.1457649","article-title":"Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments","volume":"19","author":"Tantry","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2018.09.021_bib0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11302-015-9462-7","article-title":"Blood cells: an historical account of the roles of purinergic signalling","volume":"11","author":"Burnstock","year":"2015","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.drudis.2018.09.021_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/5584_2017_98","article-title":"Structure, pharmacology and roles in physiology of the P2Y12 receptor","volume":"1051","author":"von K\u00fcgelgen","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2015.10.030","article-title":"Pharmacology and structure of P2Y receptors","volume":"104","author":"von K\u00fcgelgen","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2018.09.021_bib0110","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/ATVBAHA.115.303395","article-title":"Purinergic receptors in thrombosis and inflammation","volume":"35","author":"Hechler","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2018.05.029","article-title":"The role of agonist-induced activation and inhibition for the regulation of purinergic receptor expression in human platelets","volume":"168","author":"Koessler","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2018.09.021_bib0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature13288","article-title":"Agonist-bound structure of the human P2Y12 receptor","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2018.09.021_bib0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2018.09.021_bib0130","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fphar.2017.00846","article-title":"Arylacetamide deacetylase is involved in vicagrel bioactivation in humans","volume":"8","author":"Jiang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4330\/wjc.v8.i5.327","article-title":"P2Y12-ADP receptor antagonists: days of future and past","volume":"8","author":"Laine","year":"2016","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2217\/pgs-2018-0072","article-title":"Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions","volume":"19","author":"Klein","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drudis.2018.09.021_bib0145","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.clinthera.2018.06.001","article-title":"Effects of CYP2C19 genetic polymorphisms on the pharmacokinetic and pharmacodynamic properties of clopidogrel and its active metabolite in healthy Chinese subjects","volume":"40","author":"Song","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.drudis.2018.09.021_bib0150","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13238-017-0437-z","article-title":"Carboxylesterases in lipid metabolism: from mouse to human","volume":"9","author":"Lian","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.drudis.2018.09.021_bib0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcin.2010.12.009","article-title":"Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations","volume":"4","author":"Udaya","year":"2011","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.drudis.2018.09.021_bib0160","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.114.062596","article-title":"Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics","volume":"43","author":"Djebli","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2018.09.021_bib0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.112.201640","article-title":"Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation","volume":"344","author":"Zhu","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2018.09.021_bib0170","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1160\/TH12-08-0588","article-title":"High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials","volume":"109","author":"Trenk","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2018.09.021_bib0175","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11239-016-1460-2","article-title":"Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel","volume":"43","author":"Furuta","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.drudis.2018.09.021_bib0180","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \u2018cyclopropyl fragment\u2019 is a versatile player that frequently appears in preclinical\/clinical drug molecules","volume":"59","author":"Talele","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0185","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm300038c","article-title":"Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent","volume":"55","author":"Shan","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/jm981072s","article-title":"Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy","volume":"42","author":"Ingall","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0195","first-page":"275","article-title":"P2Y receptor antagonists in thrombosis","volume":"6","author":"Boeynaems","year":"2005","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2018.09.021_bib0200","first-page":"250","article-title":"Cangrelor AstraZeneca","volume":"2","author":"Chattaraj","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2018.09.021_bib0205","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1310\/hpj5010-922","volume":"50","author":"Baker","year":"2015","journal-title":"Cangrelor. Hosp. Pharm."},{"key":"10.1016\/j.drudis.2018.09.021_bib0210","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","article-title":"Cangrelor: a review on pharmacology and clinical trial development","volume":"11","author":"Franchi","year":"2013","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.drudis.2018.09.021_bib0215","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CRD.0000000000000142","article-title":"Cangrelor: a new route for P2Y12 inhibition","volume":"25","author":"Sible","year":"2017","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.drudis.2018.09.021_bib0220","first-page":"1254","article-title":"Cangrelor approved for use during coronary angioplasty","volume":"72","author":"Traynor","year":"2015","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.drudis.2018.09.021_bib0225","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.09.021_bib0230","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2016.11.017","article-title":"Cangrelor use since FDA approval: a single-center, real-world experience at a tertiary care hospital","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0235","doi-asserted-by":"crossref","first-page":"A2122","DOI":"10.1016\/S0735-1097(18)32663-9","article-title":"Use of Cangrelor as a bridge to gynecological surgery in a cardiac patient with recent cardiac stent placement for NSTEMI","volume":"71","author":"Leung","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0240","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/jth.12719","article-title":"Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 receptor","volume":"12","author":"Hoffmann","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2018.09.021_bib0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/14656566.2017.1421634","article-title":"Ticagrelor in modern cardiology \u2013 an up-to-date review of most important aspects of ticagrelor pharmacotherapy","volume":"19","author":"Danielak","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2018.09.021_bib0250","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.09.021_bib0255","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40262-015-0320-0","article-title":"Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic\/pharmacodynamic study","volume":"55","author":"Alexopoulos","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drudis.2018.09.021_bib0260","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11302-008-9106-2","article-title":"Development of selective agonists and antagonists of P2Y receptors","volume":"5","author":"Jacobson","year":"2009","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.drudis.2018.09.021_bib0265","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1160\/TH10-05-0285","article-title":"BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism","volume":"104","author":"Zhang","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2018.09.021_bib0270","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1160\/TH11-06-0400","article-title":"BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase","volume":"106","author":"Hu","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2018.09.021_bib0275","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/09537100701268741","article-title":"Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589","volume":"18","author":"Johnson","year":"2007","journal-title":"Platelets"},{"key":"10.1016\/j.drudis.2018.09.021_bib0280","series-title":"Inspire Terminates Phase 2 Clinical Trial for Platelet Aggregation Inhibitor","author":"Business Wire","year":"2013"},{"key":"10.1016\/j.drudis.2018.09.021_bib0285","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.thromres.2008.03.026","article-title":"Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets","volume":"122","author":"Bryant","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2018.09.021_bib0290","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.thromres.2008.04.009","article-title":"Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization","volume":"122","author":"Post","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2018.09.021_bib0295","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/jm901518t","article-title":"Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation","volume":"53","author":"Parlow","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0300","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40261-014-0236-8","article-title":"A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial","volume":"34","author":"Baldoni","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.drudis.2018.09.021_bib0305","doi-asserted-by":"crossref","first-page":"9133","DOI":"10.1021\/acs.jmedchem.5b00933","volume":"58","author":"Caroff","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0310","doi-asserted-by":"crossref","unstructured":"Choudhury, A.K.R. (2011) Dyeing of synthetic fibres, In Handbook of Textile and Industrial Dyeing (Vol. 2) (Clark, M., ed.), pp. 40\u2013128, Woodhead Publishing","DOI":"10.1533\/9780857094919.1.40"},{"key":"10.1016\/j.drudis.2018.09.021_bib0315","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.biotechadv.2018.04.001","article-title":"Naturally occurring compounds in differentiation based therapy of cancer","volume":"36","author":"Mijatovi\u0107","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.drudis.2018.09.021_bib0320","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ptr.5631","article-title":"Emodin: a review of its pharmacology, toxicity and pharmacokinetics","volume":"30","author":"Dong","year":"2016","journal-title":"Phytother. Res."},{"key":"10.1016\/j.drudis.2018.09.021_bib0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jscs.2011.12.020","article-title":"Dyeing studies with henna and madder: a research on effect of tin (II) chloride mordant","volume":"19","author":"Yusufa","year":"2015","journal-title":"J. Saudi. Chem. Soc."},{"key":"10.1016\/j.drudis.2018.09.021_bib0330","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpedsurg.2016.10.021","article-title":"Effectiveness of senna vs polyethylene glycol as laxative therapy in children with constipation related to anorectal malformation","volume":"52","author":"Santos-Jasso","year":"2017","journal-title":"J. Pediatr. Surg."},{"key":"10.1016\/j.drudis.2018.09.021_bib0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fphar.2018.00075","article-title":"Free total rhubarb anthraquinones protect intestinal injury via regulation of the intestinal immune response in a rat model of severe acute pancreatitis","volume":"9","author":"Xiong","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0340","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharmthera.2018.04.002","article-title":"Tools and drugs for uracil nucleotide-activated P2Y receptors","volume":"190","author":"Rafehi","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2018.09.021_bib0345","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jsb.2014.01.005","article-title":"Crystal structure of NTPDase2 in complex with the sulfoanthraquinone inhibitor PSB-071","volume":"185","author":"Zebisch","year":"2014","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0350","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.drudis.2016.06.027","article-title":"Anthraquinones as a privileged scaffold in drug discovery targeting nucleotide-binding proteins","volume":"21","author":"Baqi","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2018.09.021_bib0355","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm1012193","article-title":"Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor","volume":"54","author":"Baqi","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0360","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1124\/jpet.109.156687","article-title":"Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor","volume":"331","author":"Hoffmann","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2018.09.021_bib0365","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nprot.2010.63","article-title":"Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalysed Ullmann coupling reactions","volume":"5","author":"Baqi","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.drudis.2018.09.021_bib0370","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/ol070102v","article-title":"Rapid and efficient microwave-assisted copper(0)-catalysed ullmann coupling reaction: general access to anilinoanthraquinone derivatives","volume":"9","author":"Baqi","year":"2007","journal-title":"Org. Lett."},{"key":"10.1016\/j.drudis.2018.09.021_bib0375","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.3390\/molecules17032599","article-title":"Convergent synthesis of the potent P2Y receptor antagonist MG 50-3-1 based on a regioselective Ullmann coupling reaction","volume":"17","author":"Baqi","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2018.09.021_bib0380","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1021\/acs.jmedchem.7b00854","article-title":"Molecular recognition of agonists and antagonists by the nucleotide-activated g protein-coupled P2Y2 receptor","volume":"60","author":"Rafehi","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0385","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11302-008-9103-5","article-title":"Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases)","volume":"5","author":"Baqi","year":"2009","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.drudis.2018.09.021_bib0390","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1016\/j.bmc.2016.07.027","article-title":"Inhibitors for the bacterial ectonucleotidase Lp1NTPDase from Legionella pneumophila","volume":"24","author":"Fiene","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0395","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm1012193","article-title":"Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor","volume":"54","author":"Baqi","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0400","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1021\/acs.jmedchem.7b00030","article-title":"Development of potent and selective antagonists for the UTP-activated P2Y4 receptor","volume":"60","author":"Rafehi","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0405","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/jm901851t","article-title":"Development of potent and selective inhibitors of ecto-5\u2019-nucleotidase based on an anthraquinone scaffold","volume":"53","author":"Baqi","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0410","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/S0960-894X(01)00313-4","article-title":"Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y(12))","volume":"11","author":"Scarborough","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2018.09.021_bib0415","unstructured":"Houille, O. et al. Actelion Pharmaceuticals Ltd. A preparation of pyrazolidinedione derivatives, useful as platelet ADP receptor antagonists. WO 2005000281 A2 20050106"},{"key":"10.1016\/j.drudis.2018.09.021_bib0420","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/ijms17030388","article-title":"A comparative study of molecular structure, pKa, lipophilicity, solubility, absorption and polar surface area of some antiplatelet drugs","volume":"17","author":"Remko","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2018.09.021_bib0425","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MOH.0b013e32832ea2f2","article-title":"New P2Y12 antagonists","volume":"16","author":"Michelson","year":"2009","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0430","first-page":"98","article-title":"Antithrombotic therapy: current status and future developments","volume":"3","author":"Mishra","year":"2012","journal-title":"theHealth"},{"key":"10.1016\/j.drudis.2018.09.021_bib0435","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1021\/jm400820m","article-title":"Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. Separation of the antithrombotic effect and bleeding for candidate drug AZD1283","volume":"56","author":"Bach","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0440","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/jm500588w","article-title":"N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist","volume":"57","author":"Boldron","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2018.09.021_bib0445","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.thromres.2014.06.034","article-title":"SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?","volume":"134","author":"Delesque-Touchard","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2018.09.021_bib0450","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coph.2017.10.011","article-title":"Purinergic drug targets for gastrointestinal disorders","volume":"37","author":"Burnstock","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.drudis.2018.09.021_bib0455","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/CIRCRESAHA.116.309726","article-title":"Purinergic signaling in the cardiovascular system","volume":"120","author":"Burnstock","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2018.09.021_bib0460","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","article-title":"Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties","volume":"73","author":"Ferri","year":"2013","journal-title":"Drugs"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618302241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618302241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:40:00Z","timestamp":1761223200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618302241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1359644618302241"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2018.09.021","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2018.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}